SMAD6-related craniosynostosis

SMAD6-Related Craniosynostosis – Pathophysiology Overview

Disease Name: SMAD6-related craniosynostosis (also known as Craniosynostosis 7, susceptibility to, OMIM #617439). This is a Mendelian disorder (autosomal dominant with incomplete penetrance) characterized by premature fusion of the skull sutures due to pathogenic variants in the SMAD6 gene.

Core Pathophysiology

Craniosynostosis is the premature fusion of one or more cranial sutures, the fibrous joints between skull bones (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In SMAD6-related craniosynostosis, the primary pathogenic mechanism is a dysregulation of the bone morphogenetic protein (BMP) signaling pathway caused by loss-of-function mutations in SMAD6 (pmc.ncbi.nlm.nih.gov) (www.nature.com). SMAD6 encodes an inhibitory SMAD protein that normally acts as an intracellular “brake” on BMP/TGF-β signaling (www.nature.com) (www.nature.com). Under normal conditions, BMP family ligands (e.g. BMP2) bind to their receptors on osteogenic progenitor cells, triggering phosphorylation of receptor-regulated SMADs (SMAD1/5/8). These activated SMADs form complexes with SMAD4 and translocate to the nucleus to drive expression of osteogenic genes. SMAD6 counterbalances this by competing with SMAD4 and receptor-SMADs, thereby negatively regulating BMP signal transduction (www.nature.com). In patients with SMAD6 mutations, this negative feedback is impaired, leading to overactivity of BMP/TGFβ signaling in cranial suture cells (www.nature.com). As a result, osteoblast differentiation and bone formation are no longer properly restrained.

Excessive Smad-dependent BMP signaling drives the suture’s mesenchymal cells to prematurely differentiate into bone-forming osteoblasts (GO:0001649 osteoblast differentiation) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In essence, losing SMAD6 is like “releasing the brakes” on osteogenesis: the balance shifts towards unchecked bone deposition at the sutures. Studies in animal models strongly support this mechanism. In a pivotal mouse experiment, Mishina and colleagues selectively augmented BMP/Smad signaling in cranial neural crest (CNC) cells and observed craniosynostosis as a direct outcome (pmc.ncbi.nlm.nih.gov). As they reported, “failure to maintain precisely controlled Smad-dependent BMP signaling in CNC cells… led to craniosynostosis,” and reducing BMP signaling (genetically or pharmacologically) could rescue the premature suture fusion (pmc.ncbi.nlm.nih.gov). This underscores that tightly regulated BMP activity in suture progenitor cells is critical for keeping sutures open. In SMAD6 mutation cases, the lack of regulation means BMP signaling goes unchecked, causing early ossification (GO:0001503) of sutural tissue when it should remain unossified. Overall, the core pathophysiology is a developmental aberration in skull bone formation: elevated BMP pathway activity (due to loss of SMAD6 inhibition) accelerates intramembranous ossification at the sutures, fusing them before the brain has finished growing (www.nature.com).

Importantly, this mechanism is distinct from many syndromic craniosynostoses caused by FGFR mutations that hyperactivate RAS/MAPK signaling. SMAD6-related craniosynostosis fits into a broader pattern where disturbances in TGF-β/BMP (SMAD-dependent) signaling specifically affect midline sutures (pmc.ncbi.nlm.nih.gov). Indeed, rare syndromes with mutations in other SMAD pathway components (e.g. TGFBR1/2 in Loeys-Dietz syndrome, SKI in Shprintzen-Goldberg syndrome) often involve sagittal or metopic suture fusions (pmc.ncbi.nlm.nih.gov). Thus, current understanding places SMAD6 haploinsufficiency in a common pathogenic framework: excess osteogenic signaling in cranial progenitor cells leads to premature suture fusion. The SMAD6 mechanism specifically highlights the role of an inhibitory feedback loss in a developmental signaling pathway, rather than a gain-of-function in a receptor or ligand. This concept was first demonstrated by Timberlake et al. (2016), who identified SMAD6 as the top mutated gene in infants with non-syndromic midline craniosynostosis (www.nature.com) (pmc.ncbi.nlm.nih.gov). They described SMAD6 as “an inhibitor of BMP-induced osteoblast differentiation” whose disruption predisposes to suture fusion (pmc.ncbi.nlm.nih.gov). Subsequent functional studies confirmed that many pathogenic SMAD6 variants indeed reduce the protein’s ability to suppress BMP signaling in cell-based assays (www.nature.com) (www.nature.com). Taken together, the core pathophysiology can be summarized as: loss of SMAD6-mediated signal control → hyperactive BMP/SMAD pathway → accelerated osteoblast maturation and bone formation at cranial sutures → premature suture fusion.

Key Molecular Players

Genes/Proteins: The principal gene involved is SMAD6 (SMAD Family Member 6, HGNC:6772), which encodes the SMAD6 protein. SMAD6 is an intracellular signal transducer and transcriptional modulator that specifically inhibits the BMP signaling branch of the TGF-β superfamily pathway (www.nature.com). It achieves this by binding to receptor-activated SMAD1/5 and competing for partnership with the co-SMAD (SMAD4), thereby blocking the formation of active SMAD complexes that drive gene expression (www.nature.com). SMAD6 also recruits ubiquitin ligases (e.g. SMURF1) to the receptor complex, targeting it for degradation, further dampening the signal (GO:0030514 negative regulation of BMP signaling pathway)^[(Hata et al., 1998, PMID: 9427768)]. In normal physiology, BMP stimulation actually induces SMAD6 expression as a feedback mechanism – for example, BMP2 upregulates SMAD6 transcription via the osteogenic transcription factor RUNX2 (pmc.ncbi.nlm.nih.gov) – highlighting SMAD6’s role as a homeostatic “checkpoint” in bone formation. Pathogenic variants of SMAD6 are typically loss-of-function (nonsense, frameshift, or deleterious missense); these reduce the level or function of SMAD6 protein, tipping the balance in favor of pro-osteogenic signaling (www.nature.com) (www.nature.com). Notably, SMAD6 mutations show incomplete penetrance: many carriers do not develop craniosynostosis (more on this below), implying that additional factors influence the phenotype (www.nature.com) (pmc.ncbi.nlm.nih.gov).

Other genes/proteins play modifying or context-specific roles. A common variant in BMP2 (Bone Morphogenetic Protein 2, HGNC:1073), which encodes a key osteogenic growth factor, has been implicated as a second hit modifier. The risk allele (C) at SNP rs1884302 lies in an enhancer near BMP2 and is associated with elevated BMP2 expression in cranial tissue (www.nature.com). Timberlake et al. found that among SMAD6 mutation carriers, those who also inherited this BMP2 risk allele were far more likely to manifest craniosynostosis (observed in 14 of 17 affected vs. only 3 of 16 unaffected carriers) (pmc.ncbi.nlm.nih.gov). This provided evidence for a two-locus inheritance model, where rare SMAD6 variants plus a common BMP2 allele interact epistatically to cause disease (pmc.ncbi.nlm.nih.gov). In their cohort, this combination accounted for ~7% of all midline craniosynostosis cases (pmc.ncbi.nlm.nih.gov). However, later studies found that the BMP2 variant alone did not consistently predict outcomes (www.nature.com) (www.nature.com). For instance, Calpena et al. (2020) showed that many unaffected SMAD6 carriers also had the risk allele, and some affected individuals lacked it, suggesting other genetic or environmental modifiers at play (www.nature.com) (www.nature.com). Nonetheless, BMP2 remains a relevant molecular player, as its signaling is central to the pathogenesis. Elevated BMP2 (or related BMP ligands like BMP7) can exacerbate the osteogenic drive, whereas noggin (NOG) and other extracellular BMP antagonists normally help keep sutures patent (in mice, loss of Nog causes suture fusion via excess BMP signaling, analogous to the SMAD6 mechanism)^[(Warren et al., 2003, PMID: 12612584)]. Besides BMP2, genes in the BMP receptor and downstream pathway are of interest: e.g., BMPR1A (the type I receptor for BMP2/4) and SMAD1/5 (effector SMADs) are part of the cascade that SMAD6 regulates. While mutations in these effector genes have not been commonly observed in human craniosynostosis, rare variants in SMAD9 and BMPR2 (BMP type II receptor) have been reported in individuals with cardiovascular anomalies alongside SMAD6 variants (www.nature.com), suggesting possible synergistic effects. Overall, SMAD6 is the causative gene, and BMP2 and its receptor pathway constitute the critical molecular context for disease expression.

Chemical/Signaling Entities: Although craniosynostosis is primarily a genetic and developmental disorder, certain molecular entities are noteworthy. BMP2 protein (a growth factor, CHEBI:50856) is the key signaling molecule driving osteoblast differentiation in this condition. It operates as an extracellular ligand (see below) that binds to BMP receptors and activates the SMAD pathway. The SMAD6-BMP2 two-locus model highlights that increased BMP2 signal intensity (due to genetic upregulation) can precipitate suture fusion when SMAD6’s restraint is lacking (www.nature.com). No specific metabolite or dietary factor is known to trigger SMAD6-related craniosynostosis. However, in experimental settings, small-molecule inhibitors of the BMP pathway can modulate the disease process. For example, dorsomorphin (also known as compound C, CHEBI:49475) and its analogs are pharmacological inhibitors of BMP type I receptors. In the BMP-hyperactivation mouse model mentioned above, the use of a BMP pathway inhibitor was able to prevent or rescue craniosynostosis phenotypes (pmc.ncbi.nlm.nih.gov). This suggests a potential therapeutic avenue: chemically dampening BMP signaling might counteract the effects of SMAD6 loss. While such drugs are not yet in clinical use for craniosynostosis, they are relevant chemical probes for understanding the pathophysiology. Additionally, general bone metabolism factors like calcium (Ca^2+) and phosphate are end-stage contributors to ossification (CHEBI:29108 for calcium ion), but their levels are not specifically abnormal in SMAD6-related cases. In summary, the most pertinent “chemical” factors are the morphogens and inhibitors of the BMP pathway (the signals orchestrating osteogenesis) rather than traditional metabolites.

Cell Types: The cellular context of SMAD6-related craniosynostosis involves several key cell types in cranial development. Cranial neural crest cells (CNCCs; Cell Ontology: CL:0011012) are a population of embryonic progenitors that migrate into the developing head and give rise to most of the craniofacial bones and sutures (pmc.ncbi.nlm.nih.gov). Notably, the frontal bones (which meet at the metopic suture) are derived from neural crest, whereas the parietal bones (meeting at the sagittal suture) arise from paraxial mesoderm (pmc.ncbi.nlm.nih.gov). Despite these different embryonic origins, both populations require precise regulation of osteogenic signals. Experimental evidence indicates that the premature fusion originates at the level of early osteoprogenitor cells. Komatsu et al. (2013) demonstrated that enhancing BMP/Smad signaling specifically in neural crest-derived cells is sufficient to cause craniosynostosis in mice, whereas the same enhancement confined to already differentiated osteoblasts did not induce suture fusion (pmc.ncbi.nlm.nih.gov). This finding implies that pre-osteoblastic mesenchymal cells in the suture (the cells that normally remain unossified) are the crucial cell type affected. In SMAD6 mutation patients, these cells – which include suture mesenchymal cells (a mix of fibroblast-like cells and osteogenic progenitors in the suture gap) – undergo accelerated differentiation into osteoblasts (bone-forming cells, CL:0000062). The osteoblasts at the edges of skull bones (in the osteogenic fronts flanking each suture) are also affected; without SMAD6, they become hyperactive in laying down bone matrix, encroaching into the suture space. In summary, the primary affected cell types are: (1) cranial suture mesenchymal cells (including neural crest-derived mesenchyme in the frontal region and mesodermal mesenchyme in others), which fail to remain in an undifferentiated state; and (2) osteoblast lineage cells, which proliferate and mature too rapidly. Other cell types indirectly involved include dural cells (meningeal cells underlying the suture) which normally signal to sutural cells – dural signals like FGF and TGF-β help regulate suture patency, and loss of SMAD6 may skew responses to such signals. There is also evidence that SMAD6 is expressed in cardiovascular cells (neural crest contributes to heart outflow tract septation), relating to the cardiac phenotypes noted with SMAD6 variants (www.nature.com). But in the context of craniosynostosis, it is the osteoprogenitors and their precursors in the cranial suture environment that are the central cellular players.

Anatomical Locations: SMAD6-related craniosynostosis primarily involves the cranial vault sutures (anatomical joints in the skull that normally remain open in infancy). Most commonly, the midline sutures are affected: the metopic suture (UBERON:0002490, also called the frontal suture) which lies between the two frontal bones, and the sagittal suture (between the two parietal bones) (www.nature.com). Large-scale genetic studies found SMAD6 variants especially enriched in metopic synostosis – about 5–8% of infants with isolated metopic craniosynostosis carry a pathogenic SMAD6 change (www.nature.com) (pmc.ncbi.nlm.nih.gov). Sagittal synostosis is also seen, though less frequently (around 1–2% of nonsyndromic sagittal cases involve SMAD6 mutations) (www.nature.com). In practical terms, SMAD6 is recognized as one of the most common genetic causes of metopic ridge (trigonocephaly), and an important cause of sagittal synostosis as well (pmc.ncbi.nlm.nih.gov). The metopic suture runs from the top of the head down the forehead to the nose; when it fuses early, the forehead becomes keel-shaped (triangular) – a deformity known as trigonocephaly (see Phenotypes below). The sagittal suture runs along the midline of the skull vault; its premature fusion produces a long, narrow skull (scaphocephaly). Less commonly, SMAD6 variants can cause fusion of other sutures: Cases of unilateral coronal suture synostosis (joining frontal and parietal bone on one side) and even lambdoid suture synostosis have been reported in SMAD6 carriers (www.nature.com). For example, Calpena et al. (2020) described individuals with SMAD6 variants who had right unicoronal synostosis or combined sagittal + coronal fusion (www.nature.com). Thus, while midline closures are most characteristic, SMAD6-related disease can involve multiple sutures and various skull regions, sometimes mimicking syndromic craniosynostosis patterns. The cranial base (bones at the skull’s base) is generally not the primary site of pathology in isolated craniosynostosis, but subtle abnormalities can occur secondarily due to altered growth dynamics. Overall, the anatomical focus of the disease is the calvarial sutures (UBERON:0010301) and the adjacent skull bones (frontal bone – UBERON:0002419; parietal bone – UBERON:0002453). These are the locations where dysregulated bone formation leads to premature fusion.

Disrupted Biological Processes (GO Terms)

Several biological processes are perturbed in SMAD6-related craniosynostosis, corresponding to Gene Ontology (GO) categories:

• BMP signaling pathway (GO:0030509) – Upregulated: The BMP/TGF-β signaling cascade is hyperactive due to loss of inhibitor. SMAD6 normally contributes to negative regulation of BMP signaling (GO:0030514), so its absence means processes like SMAD phosphorylation, SMAD4 complex formation, and target gene transcription proceed unchecked (www.nature.com). This leads to sustained expression of BMP-responsive osteogenic genes (e.g. RUNX2, DLX5, MSX2), promoting bone formation. Timberlake et al. noted that “overactivity of [the TGFβ/BMP] pathway predispose[s] to craniosynostosis.” (www.nature.com) Indeed, any perturbation increasing BMP/SMAD activity in sutural cells (whether by removing inhibitors like SMAD6 or by excessive ligand) disrupts normal suture maintenance (pmc.ncbi.nlm.nih.gov).

• Osteoblast differentiation (GO:0001649) – Prematurely initiated/enhanced: Under normal conditions, suture mesenchymal cells keep a balance between proliferation and differentiation. In SMAD6 mutation, that balance shifts toward differentiation. The process of mesenchymal progenitors maturing into osteoblasts is accelerated. Genes associated with osteoblast maturation and bone matrix production (such as those encoding alkaline phosphatase, osteopontin, and collagens) are upregulated earlier than they should be, leading to ectopic or early ossification at the suture site (pmc.ncbi.nlm.nih.gov). Effectively, the intramembranous ossification process (GO:0061330) that normally happens gradually at the edges of sutures extends across the suture prematurely. In mouse models, this can even involve an abnormal endochondral ossification component at the sutures (pmc.ncbi.nlm.nih.gov), though in human craniosynostosis the bone formation is primarily intramembranous.

• Skull suture morphogenesis and maintenance: Although not a single GO term, the developmental process that keeps sutures open is fundamentally disrupted. This involves fibrous connective tissue development in the suture and suture patency maintenance. Normally, signaling crosstalk (FGF, WNT, TGF-β/BMP) ensures sutures remain unossified until the appropriate time (pmc.ncbi.nlm.nih.gov). In SMAD6 pathology, the balance of signals is skewed such that osseous fusion of the suture occurs when it shouldn’t. We can consider this a failure of suture maintenance (GO:0097093 – maintenance of cranial suture patency) – although that specific term is not in GO, it conceptually ties to processes like negative regulation of ossification in the suture niche. Furthermore, cell proliferation in suture mesenchyme is likely reduced since cells exit the cell cycle to differentiate (contrasting with normal sutures where progenitors continue to proliferate to accommodate skull growth).

• Cranial development processes: Higher-order processes like cranial skeleton morphogenesis (GO:0048701) and fontanelle closure timing are altered. The metopic suture normally closes in later infancy (around 1 year) (pmc.ncbi.nlm.nih.gov), but in SMAD6 cases it may close in utero or soon after birth. Thus, timing of suture fusion is shifted earlier. Biological pathways like Wnt signaling and FGF signaling also intersect with BMP in suture biology (www.nature.com); interestingly, de novo mutations in WNT pathway inhibitors (e.g. AXIN2) and RAS-ERK pathway inhibitors have been found in midline craniosynostosis alongside SMAD6 (www.nature.com). This suggests a network of pathways (BMP/SMAD, FGF/ERK, Wnt/β-catenin) that must remain balanced for sutures to remain open. SMAD6 loss tilts this network, and as a result, processes like osteogenic signaling crosstalk and extracellular matrix organization in the suture (collagenous matrix that normally keeps bones separate) are perturbed. The eventual outcome is a pathological process: premature cranial suture fusion (which could be described by the phenotype term HP:0005477). In GO terms, this outcome might be encompassed by abnormal joint fusion, but since sutures are fibrous joints, one could say there is an aberrant execution of ossification involved in closure of fontanelle (GO:0060313) – a process that, in this disease, happens at the wrong time and place.

Key Cellular Components (Subcellular Localization)

At the subcellular level, the pathophysiological process of SMAD6–related craniosynostosis involves multiple cellular compartments:

• Extracellular space (GO:0005576): This is where the BMP ligands (such as BMP2) operate. They are secreted morphogens that diffuse in the extracellular milieu of the suture mesenchyme. In the suture’s microenvironment, BMP2 and related factors bind to receptors on the cell surface. The presence of the BMP2 ligand outside cells is enhanced or more consequential in SMAD6 mutants because any BMP2 present can signal more robustly (the cells are hyper-responsive without the intracellular inhibition).

• Plasma membrane (GO:0005886): BMPs bind to a receptor complex on the cell membrane consisting of type I and type II BMP receptors (e.g., BMPR1A, BMPR2). These receptors are transmembrane serine/threonine kinases. Upon ligand binding and receptor activation, signaling is transduced across the membrane, and the receptors phosphorylate intracellular SMAD proteins. In SMAD6 normal function, SMAD6 can interfere at the membrane-proximal level by associating with the type I receptor or recruiting ubiquitin ligases (like SMURF1) to degrade the receptor, thus acting at the cell surface level to dampen signaling (pmc.ncbi.nlm.nih.gov). In SMAD6 deficiency, the receptor complex at the plasma membrane signals unabated, phosphorylating SMAD1/5 to excess.

• Cytoplasm (GO:0005737): This is the site where receptor-phosphorylated SMAD1/5 accumulate and where SMAD4 and SMAD6 reside prior to nuclear entry. In normal cells, SMAD6 localizes to the cytoplasm and can bind activated R-SMADs (SMAD1/5) there, preventing them from forming a complex with SMAD4 (www.nature.com). The SMAD6–SMAD1 interaction essentially sequesters the signal in the cytoplasm. If SMAD6 is absent or nonfunctional, phosphorylated SMAD1/5 freely form complexes with SMAD4. These complexes translocate to the nucleus. Thus, the cytosolic checkpoint is lost. Additionally, SMAD6 and SMAD7 in the cytosol can recruit E3 ubiquitin ligases (SMURFs) to the BMP receptors, targeting them for internalization and degradation (pmc.ncbi.nlm.nih.gov). Without SMAD6, that mechanism is impaired, possibly leading to prolonged receptor presence at the membrane and extended signaling.

• Nucleus (GO:0005634): This is where the downstream effects manifest in gene expression changes. Normally, once in the nucleus, SMAD1/5-SMAD4 complexes bind to DNA and regulate transcription of target genes (including those that induce osteoblast differentiation). SMAD6 also operates in the nucleus: it can enter the nucleus and directly inhibit transcriptional complexes. For example, Hata et al. (1998) showed “Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor.” (www.nature.com). This implies SMAD6 can bind to activated SMAD1 in the nucleus, displacing SMAD4 or preventing the complex from recruiting transcriptional co-factors, thereby halting transcription of BMP-responsive genes. In SMAD6-mutant cells, nuclear SMAD1/5-SMAD4 complexes are more abundant and persist longer, driving expression of osteogenic genes (like ALPL, COL1A1, OCN) at higher levels. The nucleus of osteoprogenitor cells thus sees inappropriate activation of osteogenesis programs. Additionally, SMAD6 may influence gene expression by interacting with other nuclear factors (it has a MH1 DNA-binding domain, though with unclear specificity). In summary, the loss of SMAD6 in both cytoplasm and nucleus removes critical inhibitory interactions in those compartments, allowing continuous signal propagation from the membrane to the DNA.

• Other organelles: While not central to the classic BMP/SMAD pathway, it’s worth noting that osteoblasts have active secretory pathways (ER/Golgi) to export bone matrix proteins. Upregulation of osteoblast differentiation means heightened activity in those organelles as well. There is no known direct role of SMAD6 in mitochondria or other organelles for this disease. However, the cytoskeletal component and cell shape might change as mesenchymal cells differentiate into osteoblasts (they become more polygonal/cuboidal and start organizing actin differently). These cell morphological changes, while secondary, are part of the cellular changes during suture fusion.

Disease Progression

The progression of SMAD6-related craniosynostosis is set in motion during embryonic and early postnatal development of the skull. The timing and sequence of events can be outlined as follows:

• Initiating event (genetic): A heterozygous SMAD6 mutation is present from conception, in every cell. However, its pathogenic effect is most relevant in cells of the developing cranial sutures. There is no known “second hit” somatic mutation necessary in SMAD6 (haploinsufficiency is sufficient), but as described above, a polygenic context or additional genetic factors (like the BMP2 enhancer variant) can tip the balance toward disease (www.nature.com). Thus, the “trigger” at the molecular level is when the combined signaling milieu (due to SMAD6 loss ± other factors) reaches a threshold where osteogenesis overtakes the mechanisms keeping the suture open.

• Embryonic cranial development: In utero, the fetal skull bones form by intramembranous ossification around the brain. The cranial sutures are supposed to remain as soft fibrous seams that allow expansion. In a fetus with SMAD6 haploinsufficiency, as the frontal and parietal bones grow toward each other, the reduced BMP inhibition causes the osteogenic fronts to invade too far. Typically, osteogenic fronts stop and leave a gap (suture); here, they may continue depositing bone matrix, establishing bony bridges across the suture. The exact timing may vary by suture: the metopic suture normally is the earliest to close (physiologically by 6–12 months after birth) (pmc.ncbi.nlm.nih.gov), so pathological fusion of the metopic suture in SMAD6 cases often begins prenatally or very soon after birth. The sagittal suture normally remains open until late childhood or even adulthood (pmc.ncbi.nlm.nih.gov); in SMAD6 cases, sagittal fusion likely happens in the first months of life if it is to occur. Parents often notice a ridge or abnormal head shape at birth or shortly thereafter in affected infants. For example, an infant with SMAD6-related metopic synostosis may be born with a subtle midline forehead ridge that becomes more pronounced over weeks, whereas one with sagittal synostosis might have a narrow head by a few months old. These observations suggest that the pathological fusion can be a gradual process occurring over early infancy, rather than an instantaneous event.

• Suture fusion process: Once aberrant osteoblastic activity begins at the suture, it tends to perpetuate and spread along the suture line. Locally increased BMP signaling can create a positive feedback loop (bone cells produce growth factors that induce more bone, etc.). Histologically, one would see the fibrous suture tissue being replaced by bony tissue. Islands of bone form and coalesce, until the suture is fully obliterated by bone. This process may start at one point (e.g., the nasion in metopic suture) and then extend posteriorly, or it may occur simultaneously along the suture. By the time craniosynostosis is clinically apparent, the suture is at least partially fused by a bony ridge. For instance, with metopic synostosis, a triangular forehead becomes evident as the frontal bones fuse into a single bone too early (pmc.ncbi.nlm.nih.gov). With sagittal fusion, the growing brain causes expansion compensatorily at the front and back (frontal and occipital bossing) since the parietal bones can’t spread apart, resulting in a boat-shaped skull by a few months old (pmc.ncbi.nlm.nih.gov).

• Clinical manifestation in infancy: The condition is usually diagnosed within the first year of life due to the abnormal skull shape. Triglobal (triangular) forehead and closely spaced eyes indicate metopic synostosis (trigonocephaly), whereas a dolichocephalic (long and narrow) skull indicates sagittal synostosis (pmc.ncbi.nlm.nih.gov). Parents or pediatricians may feel a hard ridge over the suture where there should be a soft gap. Neuroimaging (X-ray or CT) confirms the premature bony fusion. It's important to note that progression at this point is not a continuous worsening of the disease per se – once the suture is fused, the pathological process (bone fusion) is essentially complete. However, secondary effects progress as the child grows: because the suture cannot expand, the skull’s growth pattern is altered, which can lead to increasing cranial deformity and potential intracranial pressure (ICP) rise. The brain continues to grow rapidly in infancy, and if the skull cannot expand at a fused suture, pressure can build up. Many patients with uncorrected craniosynostosis develop signs of elevated ICP (irritability, vomiting, developmental delay). This is why the standard of care is to intervene surgically in infancy to reopen the suture.

• Intervention and post-surgical progression: Typically, around 3–9 months of age, an affected infant will undergo surgery (cranioplasty) to correct the skull shape and remove the fused suture, preventing brain constraint. After surgical correction, the progression of the disease is halted in terms of skull growth – the surgically created “new” suture or skull shape will grow more normally. However, even post-surgery, some aspects of the underlying biology remain (the genetic mutation is still present). It’s unknown if residual BMP dysregulation might affect other tissues or subtler aspects of skull development as the child grows. Ongoing research is examining whether SMAD6 mutations confer risk of re-synostosis (refusion) after surgery or influence bone healing. For now, surgical outcomes in SMAD6 patients seem similar to other craniosynostosis cases.

• Neurodevelopmental outcome: A notable aspect of disease progression is the impact on neurodevelopment. There is evidence that SMAD6-related craniosynostosis may carry a higher risk of neurodevelopmental delays compared to craniosynostosis from other causes (pmc.ncbi.nlm.nih.gov). In a recent study, children with SMAD6 mutations had, on average, more pronounced language delays than those without SMAD6 variants (pmc.ncbi.nlm.nih.gov). This could be due to prolonged elevated ICP before surgery in some cases, or possibly due to SMAD6’s role in brain development. SMAD6 is expressed in the brain and vasculature; intriguingly, some individuals with SMAD6 variants have intellectual disability even without craniosynostosis (www.nature.com). Thus, as the disease progresses, clinicians monitor cognitive and neurological development. The interplay between skull shape (which can affect brain growth mechanically) and the genetic effect on brain signaling is an area of active research.

• Incomplete penetrance and variable progression: A unique facet of SMAD6 craniosynostosis is that not everyone with the mutation develops the disease. In families, it’s common to find an asymptomatic parent (normal skull) who carries the same SMAD6 mutation as an affected child (www.nature.com). In fact, ≥20 out of 26 SMAD6 mutations in one series were inherited from an unaffected parent (www.nature.com). This means there are hidden carriers and the mutation’s effect “progresses” to actual craniosynostosis only in a subset of people. Penetrance is estimated to be around 40–60% (pmc.ncbi.nlm.nih.gov), though this can be higher in presence of certain modifiers. What determines whether an individual’s suture actually fuses is still unclear, but the two-locus model with the BMP2 variant gave a clue. For example, one study found that among SMAD6 carriers, those with the BMP2 risk allele had craniosynostosis much more often than those without (15 of 21 vs 1 of 20 in their cohort) (www.nature.com). This suggests that the progression to disease requires crossing a signaling threshold, achieved by combined genetic factors. Environmental factors (e.g. prenatal exposures) have not been definitively linked to SMAD6 penetrance, but generally, retinoic acid exposure is known to cause craniosynostosis in animal models, and thyroid hormone levels can affect skull development. Whether such factors interact with SMAD6 mutations is speculative at this point. In any case, for an individual carrier, the “disease progression” may in fact never start (if they remain asymptomatic), highlighting the complexity of genotype-phenotype correlation.

In summary, the disease progression is mostly a developmental timeline: genetic predisposition leads to an abnormally accelerated suture fusion process around birth/early infancy, resulting in a fixed anatomical defect (fused suture) that then has cascading effects on skull and brain development. Early surgical intervention alters the course favorably by mechanically correcting the skull shape, but the underlying molecular propensity (e.g. toward bone formation) could still be present. Long-term, patients typically do well after surgery, though vigilance for subtle neurocognitive issues is advised.

Phenotypic Manifestations

Clinically, SMAD6-related craniosynostosis presents with the hallmark features of premature suture fusion, often with some distinguishing patterns and associated findings. Key phenotypic manifestations include:

• Craniosynostosis (HP:0000248): by definition, all patients have premature fusion of at least one cranial suture. The specific sutures involved drive the craniofacial phenotype:
• Metopic synostosis – fusion of the metopic suture (median frontal) leads to Trigonocephaly (HP:0000243) (pmc.ncbi.nlm.nih.gov). This is a triangular or keel-shaped forehead when viewed from above. The forehead appears pointed and narrowed, and there is often hypotelorism (HP:0000601), meaning the eyes are closely spaced due to the restricted growth of the frontal bones (pmc.ncbi.nlm.nih.gov). Infants with trigonocephaly have a midline ridge on the forehead and recession of the lateral orbits, giving a pinched look to the forehead. SMAD6 mutations are a leading genetic cause of nonsyndromic trigonocephaly (pmc.ncbi.nlm.nih.gov). Notably, SMAD6-related trigonocephaly can sometimes be accompanied by minor extra-cranial findings (see below), but often it is isolated aside from the skull shape.
• Sagittal synostosis – fusion of the sagittal suture results in Scaphocephaly (HP:0004448) (pmc.ncbi.nlm.nih.gov), also called dolichocephaly. The skull becomes elongated front-to-back and narrowed side-to-side, resembling a boat shape (hence “scaphocephaly”). Parents notice a prominent forehead (frontal bossing) and a protruding back of the head (occipital bossing) with a relatively narrow width. The head circumference might still increase (since growth is diverted anterior-posteriorly), but the shape is abnormal. In SMAD6 cases, scaphocephaly can be relatively mild if only part of the suture fuses, or severe if the entire suture fuses early. It was reported that SMAD6 variants accounted for roughly 1–2% of isolated sagittal craniosynostosis (www.nature.com), making it a less common but present cause of this phenotype.
• Metopic + Sagittal – Some patients have combined midline synostoses (both metopic and sagittal fused), leading to a complex phenotype with features of both trigonocephaly and scaphocephaly. Timberlake et al. noted that SMAD6 mutations were found in up to 20% of cases with combined metopic+sagittal fusion (www.nature.com). These infants can have a very constricted skull vault since growth is restricted in both width and anterior segment; they often require more extensive cranial vault remodeling.
• Coronal synostosis – This is less typical for SMAD6, but as noted, a few cases have occurred. Unicoronal synostosis (fusion of one coronal suture) leads to anterior plagiocephaly (HP:0000273), where the forehead on the fused side is flattened and pulled backward, and the opposite forehead is bossed forward. The face may appear asymmetric with one eyebrow raised and the nose deviating towards the fused side. Bicoronal synostosis (both coronal sutures fused) results in brachycephaly (HP:0000248) – a short, wide skull with a flat forehead (because neither frontoparietal junction can expand). While coronal involvement is classically seen in syndromes like Crouzon or Apert (FGFR mutations), the few SMAD6 cases with coronal fusion demonstrate that SMAD6 loss can in some instances affect those sutures too (www.nature.com). Typically, if SMAD6 is the cause, coronal synostosis might co-occur with a midline suture fusion or other anomalies, rather than isolated coronal. It’s worth noting those cases had SMAD6 variants inherited from an unaffected parent, again underscoring variable expression (www.nature.com).

• Lambdoid synostosis – Rarely mentioned in SMAD6 context, but lambdoid (posterior) suture fusion causes a flattening at the back of the skull (often confused with positional deformity). No significant association with SMAD6 has been reported for isolated lambdoid synostosis; any mention has been in combined multi-suture cases.

• Neurodevelopmental and neurologic features: Some children with SMAD6-related craniosynostosis exhibit developmental delays or learning issues. A 2023 study found that SMAD6-positive craniosynostosis patients had significantly more language delay (onset of first words, etc.) compared to those without SMAD6 variants (pmc.ncbi.nlm.nih.gov). This suggests that SMAD6 might have roles in neural development or that the craniosynostosis in these cases was severe enough to mildly impact brain development. Additionally, in SMAD6 families, there are reports of intellectual disability (ID) in some carriers (www.nature.com). For example, a de novo SMAD6 truncating variant was described in a child with intellectual disability and subtle dysmorphisms, but without craniosynostosis (www.nature.com). Although rare, this implies that SMAD6 loss can affect the central nervous system. Mechanistically, SMAD6 is expressed in the developing brain and may influence TGF-β signaling involved in neurogenesis or neuronal survival. Clinically, one might see specific issues such as speech delay, as mentioned, or other learning difficulties that become apparent in early childhood. It’s important to note that severe cognitive impairment is not the norm in nonsyndromic craniosynostosis—many SMAD6 patients have normal intelligence—but the risk of mild developmental delay appears higher in this genetic subset (pmc.ncbi.nlm.nih.gov). Moreover, if craniosynostosis is not corrected early, chronically raised intracranial pressure can itself cause headaches, irritability, or cognitive slowing. Therefore, timely surgery is indicated not just for cosmetic reasons but to prevent potential neurological sequelae.

• Craniofacial dysmorphism: Beyond head shape, specific facial features can accompany the skull changes. In metopic synostosis, aside from trigonocephaly and hypotelorism, there can be overly narrow temporal regions (the sides of the head appear pinched) and a prominent mid-forehead ridge. In sagittal synostosis, there’s often frontal bossing (prominent forehead) and occipital protuberance, giving an elongated skull profile (pmc.ncbi.nlm.nih.gov). The face in sagittal synostosis is usually not as affected, but the head from the front can appear narrow. In coronal synostosis (if present), asymmetric orbital elevation is seen (Harlequin eye deformity on X-ray for unicoronal), and in bicoronal, exophthalmos (prominent eyes) can occur because the shallow forehead doesn’t give enough orbital roof. While SMAD6 cases are often described as “nonsyndromic” (meaning no consistent extracranial anomalies), some SMAD6-positive individuals have had additional features like a small jaw or high-arched palate, etc., but not a recognizably distinct syndrome. These could be chance findings or subtle effects of altered cranial growth on facial anatomy.

• Associated skeletal or extraskeletal anomalies: Interestingly, SMAD6 mutations have pleiotropic effects. Other malformations reported in association include:

• Radioulnar synostosis – Fusion of the radius and ulna in the forearm (a bony synostosis in the arm) has been linked to SMAD6 variants (www.nature.com). One study found SMAD6 mutations in several patients with congenital radioulnar synostosis, suggesting overlapping pathogenetic mechanisms (inappropriate bone formation between normally separate bones) (www.nature.com). It appears that depending on genetic background, a SMAD6 mutation might cause craniosynostosis in one individual and radioulnar synostosis in another, or conceivably both in the same person. This reinforces that SMAD6’s role in bone joint formation is not restricted to the skull.
• Cardiovascular defects – SMAD6 is strongly associated with congenital heart defects, particularly those involving development of the outflow tract and great arteries. Notably, SMAD6 mutations were found in patients with bicuspid aortic valve (BAV) and thoracic aortic aneurysm (www.nature.com). BAV is a condition where the aortic valve has two leaflets instead of three (a form of developmental fusion, interestingly), and it’s often asymptomatic until later in life or until aneurysm develops. Some SMAD6 mutation carriers in craniosynostosis studies have later been identified with BAV or aortic dilation, and vice versa (individuals ascertained for BAV have been found to have SMAD6 variants, sometimes with a positive family history of craniosynostosis) (www.nature.com) (www.nature.com). However, in a typical pediatric craniosynostosis presentation, heart defects are not common – if a baby has craniosynostosis and a heart defect, geneticists might suspect a syndrome like Crouzon or Loeys-Dietz. Now we know SMAD6 could be a unifying cause in some families. Routine cardiac evaluation isn’t standard for isolated craniosynostosis, but one might consider an echocardiogram if SMAD6 is identified, given this association.

• Other anomalies: There are isolated reports of SMAD6 variants in patients with microtia (small ears) and other skeletal anomalies, but these are not clearly part of a SMAD6 craniosynostosis spectrum and might be coincidental or due to additional genetic factors. In general, SMAD6-related craniosynostosis is considered nonsyndromic, meaning the craniosynostosis is the major defining feature. Yet, the discovery of these associations (arm bone fusions, heart defects) suggests we could view it as a “SMAD6 syndrome” of aberrant ossification in multiple embryonic structures. ClinGen recently classified SMAD6 as having “Definitive” evidence for craniosynostosis, including in syndromic forms (search.thegencc.org).

• Growth and development: Aside from head circumference (which may track low if the skull is constrained), general growth parameters (height, weight) are usually normal in SMAD6 craniosynostosis. This sets it apart from some syndromic forms where short stature or failure to thrive might occur. Dental development can be affected indirectly by skull shape (e.g., narrow palate in trigonocephaly could crowd teeth), but SMAD6 doesn’t directly cause the dental anomalies that some craniosynostosis syndromes do (e.g., FGFR2 Apert syndrome causes tooth fusion and crowding due to Msx2 changes). Vision can be an issue if orbital shape is distorted (e.g., astigmatism in trigonocephaly, strabismus in unicoronal synostosis), but intelligence and motor development are often normal if intracranial pressure is managed.

• Post-surgical phenotype: After treatment, the head shape is surgically normalized to a large extent, and the child’s subsequent skull growth is monitored. There is a risk of re-fusion or need for secondary surgeries in any craniosynostosis, and it’s not yet clear if SMAD6 mutations confer a higher rate of re-synostosis. Some surgeons have noted that cases with known genetic cause (like SMAD6) sometimes have a more pronounced tendency for bone regrowth, but data are limited. From a pathophysiology standpoint, since the underlying BMP signaling remains high, one could hypothesize a tendency for robust bone healing. Counterintuitively, one study found that SMAD6 mutant patients had fewer reoperations and better neurodevelopmental outcomes than those with other mutations (pubmed.ncbi.nlm.nih.gov), but more research is needed.

In conclusion, the phenotype of SMAD6-related craniosynostosis is centered on abnormal skull shape due to specific suture fusion, with trigonocephaly (metopic) and scaphocephaly (sagittal) being the signature presentations (pmc.ncbi.nlm.nih.gov). These cranial phenotypes are directly caused by the underlying molecular pathology – overzealous bone formation – and they present early in life. The condition can be isolated or can variably express in conjunction with other bone fusions or cardiovascular anomalies (reflecting SMAD6’s broader role in development). Clinicians now recognize that SMAD6 mutations substantially increase the risk for craniosynostosis in both nonsyndromic and syndromic contexts (www.nature.com), and genetic testing for SMAD6 is recommended especially in cases of midline synostosis (pmc.ncbi.nlm.nih.gov). The discovery of SMAD6’s role has not only improved diagnosis (explaining ~5% of formerly “unknown” cases) but also deepened the understanding that precise regulation of BMP signaling is crucial for keeping sutures open. This knowledge raises the prospect that modulating these pathways (perhaps with BMP inhibitors or other targeted therapies) could become part of future adjunct treatments to prevent or treat craniosynostosis, alongside the standard surgical care (pmc.ncbi.nlm.nih.gov).

Evidence: The above statements are supported by a range of studies: Timberlake et al. 2016 first reported SMAD6 mutations in craniosynostosis cases (pmc.ncbi.nlm.nih.gov), and a follow-up by Timberlake 2017 and Calpena et al. 2020 expanded the genotype-phenotype spectrum (www.nature.com) (www.nature.com). Statistical enrichment of SMAD6 in patients vs. controls (18.3-fold for loss-of-function variants) has been demonstrated (www.nature.com). Functional assays confirm that pathogenic missense variants reduce SMAD6’s inhibitory activity on BMP signaling (www.nature.com) (www.nature.com). Mouse models by Komatsu/Mishina provide in vivo mechanistic proof that BMP overactivation in sutural cells induces craniosynostosis and that reducing BMP signaling can rescue it (pmc.ncbi.nlm.nih.gov). Clinically, Di Rocco et al. 2023 found SMAD6 variants in 7 of 54 trigonocephaly patients and 0 of 47 sagittal-only patients, reinforcing the metopic predilection (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). They also observed the language delay in SMAD6 cases (pmc.ncbi.nlm.nih.gov). Furthermore, SMAD6’s involvement in other conditions like BAV/TAA (www.nature.com) and radioulnar synostosis (www.nature.com) is documented, showing the consistency of the pathophysiological theme (inadequate inhibition of TGF-β/BMP leads to anomalous fusions in different tissues). In sum, SMAD6-related craniosynostosis is a well-substantiated entity linking a defined molecular defect to a cascade of developmental disturbances, ultimately manifesting in a distinctive clinical phenotype backed by both genetic and experimental evidence. (www.nature.com) (pmc.ncbi.nlm.nih.gov)